Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

134.16 -1.00 (-0.74%)
Streaming Delayed Price Updated: 11:53 AM EDT, May 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,480,793
Open 133.60
Bid (Size) 134.15 (2)
Ask (Size) 134.18 (1)
Prev. Close 135.16
Today's Range 132.77 - 134.41
52wk Range 75.56 - 138.28
Shares Outstanding N/A
Dividend Yield 1.32%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
NeuroBo Pharmaceuticals Stock Slides Despite Animal Study Showing Wegvoy, Liver Fibrosis Success
NeuroBo says DA-1241 data shows improved liver fibrosis and additive hepatoprotective effects when combined with semaglutide. 
Via Benzinga
This Biotech Stock Is Poised For 80% Upside With Breakthrough In Obesity Drug Market, Says JPMorgan
The Structure Therapeutics stock has been identified as a potential winner in the obesity drug market. JPMorgan has given the stock a significant upside potential. 
Via Benzinga

Performance

YTD
+31.39%
+31.39%
1 Month
+7.11%
+7.11%
3 Month
+10.47%
+10.47%
6 Month
+30.53%
+30.53%
1 Year
+65.09%
+65.09%

More News

Read More
EXCLUSIVE: Roundhill Investments Launches Weight Loss ETF For Exposure To Blockbuster Drugs Like Ozempic
Via Benzinga
Topics ETFs
3 Growth Stocks That Could Be Millionaire-Makers: May Edition
Via InvestorPlace
Is Novo Nordisk Stock a Millionaire Maker?
Via The Motley Fool
Smart Money Is Betting Big In NVO Options
Via Benzinga
Here's How Much You Would Have Made Owning Novo Nordisk Stock In The Last 10 Years
Via Benzinga
Should Quality Investors Include NYSE:NVO in Their Portfolio?
Via Chartmill
Weight Loss Drugs Like Wegvoy and Zepbound Users - Nestlé Launches $5 Pizza For You
Via Benzinga
7 Reliable Blue-Chip Stocks That Cannot Miss
Via InvestorPlace
Eli Lilly Secures China Nod For Popular Weight Loss/Diabetes Drug Tirzepatide
Via Benzinga
HIMS Stock Alert: Hims & Hers Shares Rocket on Weight Loss Injections
Via InvestorPlace
7 Biotech Stocks That Could Breathe New Life Into Your Portfolio
Via InvestorPlace
Wellness Platform Hims & Hers Health Adds GLP-1 Injections For Weight Loss, Stock Soars
Via Benzinga
Genetic Profile Key To Novo Nordisk's Wegovy's Weight-Loss Effectiveness, Study Reveals
Via Benzinga
Magnificent Seven? Just Two Members Meet This Earnings Criteria
Via Investor's Business Daily
Microsoft Leads Five Stocks Near Buy Points As Market Flashes Green
Via Investor's Business Daily
EXCLUSIVE: GameStop, AMC Buzz 'May Prove To Be Short-Lived,' CEO Of Company Behind MEME ETF Tells Benzinga
Via Benzinga
Topics ETFs
Pharma Stocks Outlook: Where Are 2024’s Top Performers Headed Next?
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Elevai Labs (NASDAQ: ELAB) Acquires Rights To Develop Muscle Loss Prevention Assets For Anticipated Use In Anti-Obesity Treatments, Launches Two New Subsidiaries
Via News Direct
Meet the GLP-1 Drug That Could Be the Biggest Concern for Eli Lilly and Novo Nordisk
Via The Motley Fool
7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Patent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade
Via InvestorPlace
Topics Intellectual Property
Exposures Intellectual Property
No Wegovy Shortage in Denmark Amid High Demand, Novo Nordisk Confirms
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.